Publications by authors named "P Combe"
Article Synopsis
- The study focused on individualized dosing of niraparib for patients with platinum-sensitive recurrent ovarian cancer (PSROC), revealing that most patients required treatment modifications due to adverse events (AEs) during the first three months.
- A significant proportion of patients (62%) experienced AEs, with common issues including fatigue, insomnia, and thrombocytopenia, highlighting the physical and emotional burden of the therapy.
- The findings indicated that physicians often underestimated these symptoms, emphasizing the importance of patient self-reporting for a comprehensive understanding of treatment-related challenges.
In endemic areas, the genetic diversity among co-circulating dengue virus (DENV) strains is considerable and new, highly divergent strains are identified on a regular basis. It is thus critical to ensure that molecular diagnostic tools effectively detect virus genomes even in case of important genetic variation. Here, we tested both the pan-DENV detection capacity and the limit of detection of two real-time RT-PCR assays: (i) the commercial RealStar Altona 3.
View Article and Find Full Text PDFPurpose: Multiple studies have demonstrated that electronic patient-reported outcomes (ePROs) improve overall survival and quality of life in cancer care. However, there are no specific prospective data on remote ePRO monitoring in the older population, although they represent a significant proportion of patients with cancer.
Patients And Methods: From February 2021 to April 2022, patients age 75 years and older under active anticancer treatment were consecutively recruited in six institutions.
Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Eur J Cancer
March 2024
Article Synopsis
- - Pemigatinib is used for treating advanced or metastatic cholangiocarcinoma (CCA) in patients with FGFR2 rearrangements, and a study evaluated its effectiveness and safety in real-world settings across multiple centers in France and Italy.
- - A total of 72 patients were assessed, revealing an overall response rate (ORR) of 45.8% and disease control rate (DCR) of 84.7%, with a median overall survival (OS) of 17.1 months over a follow-up period of about 19.5 months.
- - Common side effects included fatigue, ocular issues, and skin toxicity, primarily mild, with 22.2% experiencing severe adverse events (Grade
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but known and potentially severe side effect of drugs. The recent development of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, such as ribociclib, has considerably improved the management of hormone receptor positive (HR+) and HER2 negative (HER2-) advanced breast cancer. Here, we present the case of an 83-year-old patient who developed a probable DRESS syndrome induced by ribociclib, presenting with fever, eosinophilia, rash, and hepatic cytolysis.
View Article and Find Full Text PDF